Laminin-111: A potential therapeutic agent for duchenne muscular dystrophy

Sébastien Goudenege, Yann Lamarre, Nicolas Dumont, Joël Rousseau, Jérôme Frenette, Daniel Skuk, Jacques P. Tremblay

Research output: Contribution to journalArticlepeer-review

44 Scopus citations


Duchenne muscular dystrophy (DMD) still needs effective treatments, and myoblast transplantation (MT) is considered as an approach to repair damaged skeletal muscles. DMD is due to the complete loss of dystrophin from muscles. The lack of link between the contracting apparatus and the extracellular matrix leads to frequent damage to the sarcolemma triggering muscle fiber necrosis. Laminins are major proteins in the extracellular matrix. Laminin-111 is normally present in skeletal and cardiac muscles in mice and humans but only during embryonic development. In this study, we showed that intramuscular injection of laminin-111 increased muscle strength and resistance in mdx mice. We also used laminin-111 as a coadjuvant in MT, and we showed this protein decreased considerably the repetitive cycles of degeneration, inflammatory reaction, and regeneration. Moreover, MT is significantly improved. To explain the improvement, we confirmed with the same myoblast cell batch that laminin-111 improves proliferation and drastically increases migration in vitro. These results are extremely important because DMD could be treated only by the injection of a recombinant protein, a simple and safe therapy to prevent loss of muscle function. Moreover, the improvement in MT would be significant to treat the muscles of DMD patients who are already weak.

Original languageEnglish (US)
Pages (from-to)2155-2163
Number of pages9
JournalMolecular Therapy
Issue number12
StatePublished - Dec 2010

Bibliographical note

Funding Information:
We thank Julie-Rose St-Pierre, Jean-Philippe Mathieu, and Rosalie Giguere for efficient technical assistance. We thank Marlyne Goulet for providing the rat anti-mouse Mac-1. We thank Glenn E Morris and Le Thanh Lam (MRIC Biochemistry Group, Wrexham, UK) for providing the MANDYS104 antibody. This work was supported by grants from the Association Française contre les Myopathies, the Jesse’s Journey Foundation for Gene and Cell Therapy of Canada, Muscular Dystrophy Canada and the Canadian Institute of Health Research.


Dive into the research topics of 'Laminin-111: A potential therapeutic agent for duchenne muscular dystrophy'. Together they form a unique fingerprint.

Cite this